Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments reported that the Centers for Medicare & Medicaid Services (CMS) has increased key quality ratings for its Medicare Advantage plans, which affect payments for 2027. CMS now shows the company’s PPO contract H5141 at 4.5 Stars for payment year 2027, up from 3.5 Stars in the 2026 Star Rating.
In addition, CMS’s updated guidance and system display that the 2026 Star Rating for Clover’s HMO contract H8010 has risen from 4.0 Stars to 4.5 Stars, also impacting payment year 2027 Quality Bonus Payments. These higher star ratings can support stronger revenue potential and competitiveness in the Medicare Advantage market.
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 2,360 shares of Class A common stock in an open-market transaction at a weighted average price of $4.78 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
After this sale, Reynoso directly holds 2,841,211 Clover Health shares, so the transaction represents a very small portion of her overall stake.
CLOV lists proposed sale of 2,360 Restricted Stock Units on 06/15/2026. The filing also discloses recent 10b5-1 sales by Jamie Reynoso totaling 19,472 shares across 03/18/2026, 06/11/2026, and 06/15/2026 with disclosed gross amounts.
Clover Health Investments vice president of finance and controller Joseph Frank Oldakowski reported an open-market sale of 12,102 shares of Class A Common Stock at $4.86 per share. After this transaction, he directly holds 299,067 shares.
According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of 25% of restricted stock units granted on June 16, 2025. The remaining RSUs vest in equal 6.25% quarterly installments through June 16, 2029, subject to his continued service, and the sale is described as a mandatory “sell to cover” rather than a discretionary trade.
Clover Health Investments, Corp. filed a Form 144 reporting the sale of 14,155 shares of Class A Common Stock in connection with the vesting of restricted stock units on 06/16/2026.
The filing lists the securities as traded on Nasdaq and identifies the transaction as compensation-related vesting. The filing is a resale notice under Rule 144.
Clover Health Investments, Corp. reported that on June 15, 2026, Brady Priest decided to step down as Chief Executive Officer of Clover Care Services, its home-care business, effective July 3, 2026. The company will not name a new CEO for this unit. Instead, Priest’s prior responsibilities will be reorganized and distributed among members of Clover Health’s existing executive leadership team to more closely integrate Clover Care Services with the broader business. The company stated that Priest’s departure is not due to any disagreement regarding operations, policies, or practices. Clover also included standard forward-looking statement language emphasizing that anticipated benefits from the new organizational structure are subject to risks and uncertainties outlined in its SEC filings.
Clover Health Investments’ Chief Legal Officer Karen Soares reported a mandated share sale tied to tax withholding. She sold 4,681 shares of Class A common stock in open-market transactions at a weighted average price of about $4.61 per share, with trades ranging from $4.61 to $4.64.
The company’s equity incentive plan required these “sell to cover” transactions to satisfy tax obligations from vesting restricted stock units, so they were not discretionary trades. Following the sale, Soares directly holds 1,567,741 shares of Clover Health Class A common stock.
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, reported a small sale of Class A common stock. On June 15, 2026, Reynoso sold 6,350 shares in open-market transactions at a weighted average price around $4.61 per share.
According to the disclosure, these shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans, and are described as non-discretionary “sell to cover” transactions. After this activity, Reynoso directly holds 2,843,571 shares of Clover Health Class A common stock.
Clover Health Investments, Corp. reported a proposed sale of Class A Common Stock tied to the vesting of Restricted Stock Units on 06/15/2026. The filing lists 5,342 shares and references Nasdaq as the market.
Clover Health Investments, Corp. files a Form 144 notice for Class A Common Stock related to the vesting of restricted stock units. The filing lists 7,556 shares of Class A Common Stock with a proposed sale date of 06/15/2026. The excerpt also shows prior sales by Jamie Reynoso of 5,833 shares on 03/18/2026 and 7,289 shares on 06/11/2026.